Recombinant human brain natriuretic peptide (rhBNP) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 215 | Tetralogy of Fallot | 1 |
215. Tetralogy of Fallot
Clinical trials : 22 / Drugs : 48 - (DrugBank : 19) / Drug target genes : 18 - Drug target pathways : 49
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01941576 (ClinicalTrials.gov) | September 1, 2013 | 3/9/2013 | Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot | Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot | Congenital Heart Defects;Tetralogy Of Fallot | Drug: recombinant human brain natriuretic peptide (rhBNP);Drug: Placebo (0.9% sodium chloride) | Shanghai Jiao Tong University School of Medicine | NULL | Completed | 1 Month | 18 Years | All | 120 | N/A | China |